이전에 치료받지 않은 만성 림프구성 백혈병 성인 환자에서 Sonrotoclax(BGB-11417)와 Zanubrutinib(BGB-3111) 병용 요법과 Venetoclax와 Acalabrutinib 병용 요법을 비교하는 연구
이전에 치료받지 않은 만성 림프구성 백혈병 환자에서 Sonrotoclax(BGB-11417)와 Zanubrutinib(BGB-3111) 병용 요법과 Venetoclax 및 Acalabrutinib 병용 요법을 비교한 제3상 개방형 무작위 연구
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Study Director
- 전화번호: 8778285568
- 이메일: clinicaltrials@beonemed.com
연구 장소
-
-
-
Almere Stad, 네덜란드, 1315 RA
- 모병
- Flevoziekenhuis
-
Dordrecht, 네덜란드, 3318 AT
- 모병
- Albert Schweitzer Ziekenhuis
-
Sgravenhage, 네덜란드, 2545 AA
- 모병
- Hagaziekenhuis
-
-
-
-
-
Auckland, 뉴질랜드, 1023
- 모병
- Auckland City Hospital
-
Auckland, 뉴질랜드, 0622
- 모병
- North Shore Hospital
-
Christchurch, 뉴질랜드, 8011
- 모병
- Health New Zealand Canterbury
-
Dunedin, 뉴질랜드, 9016
- 모병
- Dunedin Hospital
-
Wellington, 뉴질랜드, 6021
- 모병
- Wellington Regional Hospital (Ccdhb)
-
-
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, 대한민국, 13620
- 모병
- Seoul National University Bundang Hospital
-
-
Seoul Teugbyeolsi
-
SeochoGu, Seoul Teugbyeolsi, 대한민국, 06591
- 모병
- The Catholic University of Korea, Seoul St Marys Hospital
-
SeodaemunGu, Seoul Teugbyeolsi, 대한민국, 03722
- 모병
- Severance Hospital Yonsei University Health System
-
Seoul, Seoul Teugbyeolsi, 대한민국, 03080
- 모병
- Seoul National University Hospital
-
SongpaGu, Seoul Teugbyeolsi, 대한민국, 05505
- 모병
- Asan Medical Center
-
-
-
-
-
Deggendorf, 독일, 94469
- 모병
- Donauisar Klinikum Deggendorf Klinik Fur Onkologie Und Hamatologie
-
Frankfurt am Main, 독일, 60389
- 모병
- Centrum Fur Haematologie Und Onkologie Bethanien
-
Münster, 독일, 48153
- 모병
- Geho Munster
-
Straubing, 독일, 94315
- 모병
- Klinikum St Elisabeth Straubing Gmbh Mvz Klinikum Straubing Gmbh
-
-
-
-
-
Bucharest, 루마니아, 30171
- 모병
- Coltea Clinical Hospital
-
Bucureti, 루마니아, 022328
- 모병
- Institutul Clinic Fundeni
-
ClujNapoca, 루마니아, 400015
- 모병
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca
-
-
-
-
California
-
Duarte, California, 미국, 91010-3012
- 모병
- City of Hope National Medical Center
-
Orange, California, 미국, 92868-3201
- 모병
- Chao Family Comprehensive Cancer Center
-
Palo Alto, California, 미국, 94304-2205
- 모병
- Stanford Cancer Institute
-
-
Colorado
-
Aurora, Colorado, 미국, 80012-5405
- 모병
- Rocky Mountain Cancer Centers (Williams) Usor
-
-
Florida
-
Jacksonville, Florida, 미국, 32224-1865
- 모병
- Mayo Clinic Jacksonville
-
Miami, Florida, 미국, 33140
- 모병
- Mount Sinai Medical Center Braman Comprehensive Cancer Center
-
Tampa, Florida, 미국, 33612-9496
- 모병
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Northwestern University
-
Zion, Illinois, 미국, 60099-2676
- 모병
- Midwestern Regional Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70121-2429
- 모병
- Ochsner Clinic Foundation
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215-5418
- 모병
- Dana Farber Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905-0001
- 모병
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68198
- 모병
- University of Nebraska Medical Center
-
-
New York
-
New York, New York, 미국, 10032
- 모병
- Columbia University Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28204-2990
- 모병
- Atrium Health Levine Cancer Institute (Lci)
-
Durham, North Carolina, 미국, 27705-3976
- 모병
- Duke University Medical Center
-
-
Oregon
-
Eugene, Oregon, 미국, 97401
- 모병
- Oncology Associates of Oregon Willamette Valley Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15232-1309
- 모병
- Upmc Hillman Cancer Center(Univ of Pittsburgh)
-
-
Texas
-
Tyler, Texas, 미국, 75702-7522
- 모병
- Texas Oncology Tyler
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112-5550
- 모병
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, 미국, 98109-4433
- 모병
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226-3522
- 모병
- Medical College of Wisconsin
-
-
-
-
-
Brasília, 브라질, 70390140
- 모병
- Instituto Dor de Pesquisa E Ensino Distrito Federal
-
Porto Alegre, 브라질, 90110-270
- 모병
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Salvador, 브라질, 41950-640
- 모병
- Ensino E Terapia de Inovacao Clinica Amo Etica
-
São Paulo, 브라질, 05652-900
- 모병
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, 브라질, 01401-004
- 모병
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
-
-
-
-
Stockholm, 스웨덴, 171 76
- 모병
- Karolinska Universitetssjukhuset Solna
-
-
-
-
-
Granada, 스페인, 18014
- 모병
- Hospital Universitario Virgen de Las Nieves
-
Madrid, 스페인, 28041
- 모병
- Hospital Universitario 12 de Octubre
-
Majadahonda, 스페인, 28222
- 모병
- Hospital Universitario Puerta de Hierro Majadahonda
-
Murcia, 스페인, 30120
- 모병
- Hospital Clinico Universitario Virgen de La Arrixaca
-
-
-
-
-
Birmingham, 영국, B15 2TH
- 모병
- Queen Elizabeth Hospital
-
Bournemouth, 영국, BH7 7DW
- 모병
- University Hospitals Dorset Royal Bournemouth Hospital
-
Leeds, 영국, LS9 7TF
- 모병
- St Jamess University Hospital
-
London, 영국, SE5 9RS
- 모병
- Kings College Hospital
-
Norwich, 영국, NR4 7UY
- 모병
- Norfolk and Norwich University Hospitals Nhs Foundation Trust
-
-
-
-
-
Bologna, 이탈리아, 40138
- 모병
- Irccs Azienda Ospedaliero Universitaria Bologna
-
Florence, 이탈리아, 50134
- 모병
- Aou Careggi, Servizio Sanitario Toscana
-
Milan, 이탈리아, 20132
- 모병
- Ospedale San Raffaele
-
Milan, 이탈리아, 20162
- 모병
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
-
Padova, 이탈리아, 35128
- 모병
- Azienda Ospedaliera Di Padova
-
Roma, 이탈리아, 00168
- 모병
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100730
- 모병
- Peking Union Medical College Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, 중국, 630014
- 모병
- The First Affiliated Hospital of Chongqing Medical University
-
-
Fujian
-
Fuzhou, Fujian, 중국, 350005
- 모병
- The First Affiliated Hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, 중국, 510555
- 모병
- Sun Yat Sen University Cancer Center Huangpu Branch
-
Guangzhou, Guangdong, 중국, 510000
- 모집하지 않고 적극적으로
- Zhujiang Hospital of Southern Medical University
-
-
Guangxi
-
Nanning, Guangxi, 중국, 530021
- 모병
- The First Affiliated Hospital of Guangxi Medical University
-
-
Guizhou
-
Guiyang, Guizhou, 중국, 550002
- 모병
- Guizhou Provincial Peoples Hospital
-
-
Heilongjiang
-
Harbin, Heilongjiang, 중국, 150000
- 모병
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, 중국, 450000
- 모병
- Henan Cancer Hospital
-
-
Hunan
-
Changsha, Hunan, 중국, 410011
- 모병
- The Second Xiangya Hospital of Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, 중국, 210029
- 모병
- Jiangsu Province Hospital
-
Nantong, Jiangsu, 중국, 201203
- 모병
- Affiliated Hospital of Nantong University
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국, 330006
- 모병
- The Second Affiliated Hospital of Nanchang University
-
-
Shaanxi
-
Xi'an, Shaanxi, 중국, 710004
- 모병
- The Second Affiliated Hospital of Xian Jiaotong University
-
-
Shandong
-
Jinan, Shandong, 중국, 250000
- 모병
- Shandong Provincial Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200025
- 모병
- Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
-
-
Sichuan
-
Chengdu, Sichuan, 중국, 610071
- 모병
- Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, 중국, 300020
- 모병
- Institute of Hematology and Hospital of Blood Disease
-
-
Yunnan
-
Kunming, Yunnan, 중국, 650032
- 모병
- First Affiliated Hospital of Kunming Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, 중국, 310002
- 모병
- The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan
-
-
-
-
-
Brno, 체코, 625 00
- 모병
- Fakultni Nemocnice Brno
-
Hradec Králové, 체코, 500 03
- 모병
- Fakultni Nemocnice Hradec Kralove
-
Olomouc, 체코, 77900
- 모병
- Fakultni Nemocnice Olomouc
-
Ostrava, 체코, 708 00
- 모병
- Fakultni Nemocnice Ostrava
-
PLZE, 체코, 323 00
- 모병
- Fakultni Nemocnice Plzen
-
Prague, 체코, 10000
- 모병
- Vseobecna Fakultni Nemocnice V Praze
-
-
-
-
British Columbia
-
Victoria, British Columbia, 캐나다, V8R 6V5
- 모병
- Bc Cancer Victoria
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8V 5C2
- 모병
- Juravinski Cancer Centre
-
-
Quebec
-
Montreal, Quebec, 캐나다, QC H3t 1E2
- 모병
- Jewish General Hospital
-
Montreal, Quebec, 캐나다, H4J 1C5
- 모병
- Ciusss Nim Hscm
-
Québec, Quebec, 캐나다, G1J 1Z4
- 모병
- Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)
-
Sherbrooke, Quebec, 캐나다, J1H 5N4
- 모병
- Ciusss de Lestrie Chus
-
-
-
-
-
Brzozów, 폴란드, 36-200
- 모병
- Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
-
Katowice, 폴란드, 40-519
- 모병
- Pratia Onkologia Katowice
-
Krakow, 폴란드, 30-727
- 모병
- Pratia McM Krakow
-
Lublin, 폴란드, 20-090
- 모병
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
-
Wroclaw, 폴란드, 50-367
- 모병
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
-
Bordeaux, 프랑스, 33076
- 모병
- Centre de Lutte Contre Le Cancer Institut Bergonie
-
ClermontFerrand, 프랑스, 63100
- 모병
- Chu Clermont Ferrand Therapie Cellulaire and Hematolo
-
Le Mans, 프랑스, 72037
- 모병
- Centre Hospitalier Le Mans
-
Lille, 프랑스, 59000
- 모병
- Hopital Claude Huriez Chu Lille
-
Lyon, 프랑스, 69373
- 모병
- Centre Leon Berard
-
Montpellier, 프랑스, 34090
- 모병
- Chu Montpellier Hopital Saint Eloi
-
Toulouse, 프랑스, 31100
- 모병
- Iuc Toulouse Oncopole
-
-
-
-
New South Wales
-
Blacktown, New South Wales, 호주, NSW 2148
- 모병
- Blacktown Cancer and Haematology Centre
-
Concord, New South Wales, 호주, NSW 2139
- 모병
- Concord Repatriation General Hospital
-
St Leonards, New South Wales, 호주, NSW 2065
- 모병
- Genesiscare North Shore
-
-
Queensland
-
Woolloongabba, Queensland, 호주, QLD 4102
- 모병
- Princess Alexandra Hospital
-
-
Victoria
-
Clayton, Victoria, 호주, VIC 3168
- 모병
- Monash Health
-
Heidelberg, Victoria, 호주, VIC 3084
- 모병
- Austin Health
-
Malvern, Victoria, 호주, VIC 3144
- 모병
- Cabrini Hospital Malvern
-
Melbourne, Victoria, 호주, VIC 3004
- 모병
- The Alfred Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
- Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
- Measurable disease by Computer Tomography/Magnetic Resonance Imaging
- Adequate bone marrow and organ function
Exclusion Criteria:
- Previous systemic treatment for CLL
- Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
- Known central nervous system involvement
- History of confirmed progressive multifocal leukoencephalopathy (PML)
- Uncontrolled hypertension or clinically significant cardiovascular disease
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Arm A: Sonrotoclax plus Zanubrutinib
Participants will receive sonrotoclax and zanubrutinib for a fixed duration followed by observation. |
Administered orally.
다른 이름들:
Administered orally.
다른 이름들:
|
|
활성 비교기: Arm B: Venetoclax plus Acalabrutinib
Participants will receive venetoclax and acalabrutinib for a fixed duration followed by observation. |
Administered orally.
다른 이름들:
Administered orally.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC)
기간: Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Rate of Undetectable Minimal Residual Disease at < 10^-4 sensitivity (uMRD4)
기간: Up to approximately 16 months
|
Rate of uMRD4 is defined as the percentage of participants that achieved uMRD4 measured in both peripheral blood (PB) and bone marrow aspirate (BMA) at the post-treatment follow-up visit (PTFU1) based on next generation sequencing (NGS). |
Up to approximately 16 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PFS in High-Risk Participants
기간: Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Overall Survival (OS)
기간: Up to approximately 70 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 70 months
|
|
Overall Response Rate (ORR) as Determined by IRC
기간: Up to approximately 70 months
|
ORR is defined as the percentage of participants with a complete response (CR), complete response with incomplete hematopoietic recovery (CRi), nodal partial response (nPR), or partial response (PR), before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by IRC. |
Up to approximately 70 months
|
|
Rate of Undetectable Minimal Residual Disease at < 10^-5 sensitivity (uMRD5)
기간: Up to approximately 16 months
|
Rate of uMRD5 is defined as the percentage of participants who achieved uMRD5 measured in both PB and BMA at the PTFU1 Visit based on NGS, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier). |
Up to approximately 16 months
|
|
Number of Participants with Adverse Events
기간: Up to approximately 70 months
|
Number of participants with treatment-emergent adverse events (TEAEs), adverse events of clinical interest, and serious adverse events (SAEs), including laboratory values, vital signs, and physical examination findings. |
Up to approximately 70 months
|
|
PFS Determined by Investigator Assessment
기간: Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by investigator or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Complete Response Rate (CRR) by IRC and Investigator Assessment
기간: Up to approximately 70 months
|
CRR is defined as the percentage of participants with a CR or CRi before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier). |
Up to approximately 70 months
|
|
ORR Determined by Investigator Assessment
기간: Up to approximately 70 months
|
ORR is defined as the percentage of participants with a complete response or partial response, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by investigator. |
Up to approximately 70 months
|
|
Duration of Response (DOR)
기간: Up to approximately 70 months
|
Duration of response (determined by both IRC and investigator assessment) is defined as the time from the first qualifying response (CR, CRi, nPR, or PR) until CLL progression or death. DOR analysis will only include responders. |
Up to approximately 70 months
|
|
Time to Next Treatment (TTNT)
기간: Up to approximately 70 months
|
TTNT is defined as the time from randomization to the start of the next treatment for CLL. |
Up to approximately 70 months
|
|
Change from Baseline in Score on European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL)-409 Questionnaire
기간: At baseline and up to approximately 70 months
|
Patient-reported symptoms of global health status (GHS), role functioning, and physical functioning, symptom burden and physical condition/fatigue will be measured using the European Organization for Research and Treatment of Cancer quality of life questionnaire EORTC IL-409 (an itemized version of [EORTC] quality of life questionnaire core 30 [QLQ-C30] and its CLL module CLL17). The EORTC-IL-409 consists of 17 questions answered on a 4-point scale where 1 = Not at all (best) to 4 = Very Much (worst) and 2 global health questions answered on a 7-point scale where 1 = Very poor (worst) to 7 = Excellent (best). Higher scores in GHS and functional scales and lower scores in symptom scales indicate better quality of life. |
At baseline and up to approximately 70 months
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Study Director, BeOne Medicines
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- BGB-11417-304
- 2025-524366-21-00 (씨티스)
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
IPD 공유 기간
See plan description
IPD 공유 액세스 기준
See plan description
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .